Literature DB >> 27312913

Phosphate Removal During Long Nocturnal Hemodialysis/Hemodiafiltration: A Study With Total Dialysate Collection.

Tina Zupančič1,2, Rafael Ponikvar1, Jakob Gubenšek1,2, Jadranka Buturović-Ponikvar1,2.   

Abstract

The aim of our prospective study was to quantify phosphate removal during long nocturnal high-flux hemodialysis or hemodiafiltration (HD) with total dialysate collection. Eight patients (two women) were studied for the first-in-the-week HD session that lasted 7-8 h. Total dialysate was collected. Serum and collected dialysate phosphate concentrations were measured every hour. Phosphate removal as assessed from the serum concentration was most important during the first 2 h of HD, and then a plateau was reached. The highest average phosphate concentration in the total dialysate was in the 1(st) hour, thereafter the concentration decreased but remained stable. The average total removed mass of phosphate quantified from hourly collected dialysate was 5195.7 ± 1898 mg. Phosphate had been removed in a consistent manner during the whole duration of nocturnal HD as assessed through dialysate (despite stable serum phosphate concentration). This could indicate phosphate transfer from intracellular space. The total removed phosphate quantified from the total dialysate collection was higher than previously reported and exceeded the normal phosphate food intake.
© 2016 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Entities:  

Keywords:  Hemodiafiltration; Hemodialysis; Nocturnal hemodialysis; Phosphate

Mesh:

Substances:

Year:  2016        PMID: 27312913     DOI: 10.1111/1744-9987.12435

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  3 in total

1.  Long-Term In-Center Nocturnal Hemodialysis Improves Renal Anemia and Malnutrition and Life Quality of Older Patients with Chronic Renal Failure.

Authors:  Yu Gong; Liangyu Xie; Shengqiang Yu
Journal:  Clin Interv Aging       Date:  2022-06-03       Impact factor: 3.829

2.  EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients.

Authors:  Kathleen M Hill Gallant; Elizabeth R Stremke; Laurie L Trevino; Ranjani N Moorthi; Simit Doshi; Meryl E Wastney; Nozomi Hisada; Jotaro Sato; Yoshitaka Ogita; Naohisa Fujii; Yuya Matsuda; Takei Kake; Sharon M Moe
Journal:  Kidney Int       Date:  2020-10-31       Impact factor: 10.612

3.  Control of hyperphosphatemia and maintenance of calcemia in CKD.

Authors:  Aluizio Barbosa Carvalho; Fabiana Baggio Nerbass; Lilian Cuppari
Journal:  J Bras Nefrol       Date:  2021-12-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.